e-learning
resources
Virtual 2020
Pre-Congress Content
Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Characterising individual response to mepolizumab treatment
D. Jackson (London, United Kingdom), R. Price (Stevenage, Hertfordshire, United Kingdom), S. Yancey (Research Triangle Park, NC, United States of America), R. Buhl (Mainz, Germany), S. Wenzel (Pittsburgh, PA, United States of America)
Source:
Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Session:
Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Session type:
E-poster session
Number:
2259
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Jackson (London, United Kingdom), R. Price (Stevenage, Hertfordshire, United Kingdom), S. Yancey (Research Triangle Park, NC, United States of America), R. Buhl (Mainz, Germany), S. Wenzel (Pittsburgh, PA, United States of America). Characterising individual response to mepolizumab treatment. 2259
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Durability of mepolizumab treatment response between doses
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Early treatment response may predict long-term mepolizumab benefit in severe asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Real-world treatment patterns of mepolizumab therapy in Canada
Source: Virtual Congress 2020 – Management of chronic lung conditions
Year: 2020
Relationship between pre-treatment specific IgE and the response to omalizumab therapy
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Patient characteristics that can predict response to omalizumab an (anti-IgE antibody) for achieving better control of asthmatic patients
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Eosinophils as a predictor of mepolizumab treatment responses in COPD
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018
The effectiveness of different clinical measures in evaluating response to omalizumab
Source: Annual Congress 2010 - Questionnaires use and psychological aspects in asthma
Year: 2010
Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019
Year: 2020
Real-world treatment patterns of benralizumab therapy for patients with severe asthma
Source: Virtual Congress 2020 – Diagnosis and management of asthma
Year: 2020
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008
Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?
Source: Eur Respir J 2016; 48: 1242-1245
Year: 2016
Distribution of therapeutic response in asthma control
Source: Eur Respir J 2003; 22: 568
Year: 2003
Oral glucocorticoid-sparing effects of mepolizumab. A real-life study.
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018
Response to mepolizumab treatment is sustained across 4-weekly dosing periods
Source: ERJ Open Res, 6 (3) 00068-2020; 10.1183/23120541.00068-2020
Year: 2020
Impact of omalizumab treatment persistence on asthma control
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012
Asthma control and lung function after step down from high dose ICS/LABA combination therapy
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept